|
|
|
| Efficacy of Recombinant Human Interferon Alpha-2b Vaginal Effervescent Capsule Combined with Lactobacillus Vaginal Capsule in the Treatment of Cervical HPV Infection |
| WANG Xiujuan |
| Beijing Aerospace General Hospital, Beijing 100076, China |
|
|
|
|
Abstract Objective: To observe the efficacy of recombinant human interferon alpha-2b vaginal effervescent capsule combined with Lactobacillus vaginal capsule in the treatment of cervical HPV infection and the improvement of vaginal microecology. Methods: The subjects were selected from May 2016 to May 2018 in our hospital for the treatment of cervical high-risk HPV infection, including 140 cases. According to the different treatments, they were randomly divided into control group (70 cases) and treatment group (70 cases). Patients in the control group were given recombinant human interferon alpha-2b vaginal effervescent capsules, one capsule per day for a course of 10 days within a total of three courses of treatment. For the treatment group, Lactobacillus vaginal capsules were taken on the basis of the treatment of the control group, once a night for a course of 7 days within four courses of treatment; after one month of treatment, the effect of treatment was evaluated accordingly. The main method of evaluation is to reexamine the vaginal microorganisms of patients, at the same time to reexamine the cervical HPV negative transformation of patients, and to reexamine the expression of immunoinflammatory factors. Results: After treatment, 44 cases in the treatment group turned negative, and the effective rate was 90% (19 cases ), while 34 cases in the control group turned negative, 17 cases effective; the difference between the two groups was significant (P<0.05). After treatment of a month, for the treatment group, 64 cases of vaginal microbes returned to normal, with a return to normal rate of 91.4%, while 43 cases in the control group returned to normal, with a return to normal rate of 61.4%. The pH value of vaginal secretion in the treatment group was 4.1±0.6) and that in the control group was 4.6±0.7). The normal vaginal PH value was restored in the treatment group. Nugent score of the two groups was (2.2 ±0.4) in the treatment group, which was lower than (2.9 + 0.8) in the control group. There was a significant difference between the two groups (P<0.05). After one month of treatment, IL-4 decreased significantly in both groups, while IL-12 and IFN-gamma increased significantly in both groups. Compared with the control group, the treatment group had a much larger extent (P<0.05). Conclusion: Recombinant human interferon alpha-2b vaginal effervescent capsule combined with Lactobacillus vaginal capsule is effective in the treatment of cervical HPV infection and can improve vaginal microecosystem.
|
|
|
|
|
|
[1] 赵涵.贞芪扶正胶囊联合重组人干扰素α2b阴道泡腾胶囊治疗宫颈HPV感染疗效观察[J].现代中西医结合杂志,2018,27(32):3603~3605.
[2] 霍艳芬,霍墨杰,苏俊泽.重组人干扰素α-2b凝胶联合乳酸菌阴道胶囊治疗高危型人乳头瘤病毒感染的临床观察[J].中国计划生育和妇产科,2018,10(5):45~48.
[3] 冯春妮,杨有莲.宫颈病变影响因素分析[J].世界最新医学信息文摘,2018,18(88):76~77.
[4] 王爽,袁学华,柯盈月,等.阴道微生态异常与高危型人乳头瘤病毒感染及宫颈病变的关系[J].中国微生态学杂志,2018,30(8):959~963.
[5] 徐秋霞,张升平.重组人干扰素α-2b阴道泡腾胶囊对HPV感染宫颈病变患者的临床疗效[J].海峡药学,2018,30(5):109~111.
[6] 卢玉.宫颈HR-HPV持续感染者阴道微生态状况分析[D].遵义医学院,2018.
[7] 赵文华.宫颈人乳头瘤病毒感染与阴道微生态的相关性研究[J].内蒙古医科大学学报,2018,40(2):136~138.
[8] 金镇英.重组人干扰素α-2b阴道泡腾胶囊治疗宫颈HPV感染效果观察[J].基层医学论坛,2017,21(14):1805~1806.
[9] 彭凌燕.重组人干扰素联合途径给药治疗慢性宫颈炎合并高危型HPV感染[J].数理医药学杂志,2020,33(12):1806~1808. |
|
|
|
2021, Vol. 27 
